NOVAVAX INC — Quarterly report (10-Q) — NOVAVAX INC filed its quarterly report (Form 10-Q) with the SEC on August 6, 2026, for the second quarter of fiscal year 2026, ended June 30, 2026. The company reported revenue of $56.7 million, representing a 76% declin (SEC EDGAR, 2026-08-06)
Moderna beats quarterly revenue estimates on COVID vaccine strength — Moderna reported second-quarter revenue of $145 million, exceeding analysts' average estimate of $103 million, supported by stronger-than-expected sales of its COVID-19 vaccine. Despite the revenue beat, the company's sh (Reuters, 2026-07-31)
Moderna Narrows Loss, Says New Norovirus Vaccine Didn't Meet Expectations — Moderna narrowed its second-quarter loss to $782 million while revenue climbed 2.1% to $145 million, aided by deliveries under a U.K. government contract. The company's stock rose 6.29% following the report. However, Mod (The Wall Street Journal, 2026-07-31)
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026 — Novavax, Inc. (Nasdaq: NVAX) announced it will release its second quarter 2026 financial results before U.S. markets open on Thursday, August 6, 2026. Following the release, management will host a webcast and conference (PR Newswire, 2026-07-30)
Pfizer, BioNTech Updated Covid Vaccine Gets Europe Approval — The European Commission has approved Pfizer and BioNTech's updated COVID-19 vaccine for the 2026 to 2027 season. The vaccine targets the XFG variant, and the companies said data indicate the formula generates a strong im (Morningstar, 2026-07-29)